Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 3(3)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00607971Phase 3Terminated

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Role: lead

NCT00299013Phase 3Completed

Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis

Role: lead

NCT00268879Phase 3Completed

Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)

Role: lead

NCT00163280Phase 2Completed

Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis

Role: lead

NCT00148382Phase 1Completed

Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

Role: lead

NCT00156897Phase 2Completed

Efficacy and Safety of ATL-962 in Obese Diabetics

Role: lead

All 6 trials loaded